



We
follow the
science



and put
patients
first

Contents

Climate and nature action	3
Health equity and Health systems resilience	7
How we do business	8

We've met 17 (out of 24) of our current Sustainability targets that expired in 2025. We are embedding learnings from the past five years as we develop our Sustainability targets to 2030. We expect to communicate outcomes later in 2026.

KPMG performed an independent limited assurance engagement over AstraZeneca's Sustainability Statement contained within the Annual Report 2025. Metrics marked in this document with (Δ) formed part of the AstraZeneca's Sustainability Statement over which KPMG provided limited assurance and have been extracted from the Annual Report 2025. This assurance report and basis of preparation are included on pages 205-221 of the [Annual Report 2025](#)

KPMG performed a separate independent limited assurance engagement over selected sustainability information contained within the Sustainability Data Annex 2025. Metrics are marked with (●) form part of this assurance engagement. This assurance report and Sustainability Data Reporting Criteria 2025 are available on [our website](#).

Climate and nature action

Target	Year	Progress	Status
Reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 98% from 2015 base year.	2026	Reduced Scope 1 and 2 GHG emissions (market-based) by 88.1% since 2015. We face localised challenges in securing renewable energy for our sites and in procuring and operating electric vehicles. These transition risks may hinder reductions in our Scope 1 and 2 GHG emissions and affect our ability to meet the 2026 target.	On plan
100% electric road fleet where technically feasible.	2025	81.5% of our global vehicle fleet are battery electric vehicles, representing more than 18,000 vehicles in operation worldwide. While we continue to transition globally, some markets are experiencing challenges with the supply of vehicles and the availability of charging infrastructure.	Target not met
Reduce total energy consumption from sites by 10% from 2015.	2025	Total energy consumption from sites was 1,470,181 MWh, representing a 20% reduction from the 2015 baseline.	Target met
Double energy productivity at sites from 2015.	2025	Our site's energy productivity has more than doubled, increasing from 14.90 to 39.95 (total revenue per GWh).	Target met
100% renewable electricity consumption from sites globally.	2025	94% of on-site electricity consumption was generated by renewable sources. The remaining volume reflects limitations in the availability of energy attribute certificates that meet the RE100 criteria in a small number of markets, and on-site self-generation not supplied by biomethane. We remain dedicated to maximising our renewable electricity consumption across sites globally, in line with our ambition to reduce our greenhouse gas emissions and achieve net zero by 2045.	Target not met
Reduce absolute Scope 3 GHG emissions by 50% from 2019 base year.	2030	Total Scope 3 within target boundary is 6,070,258 tonnes CO ₂ e, representing a 24% increase from the 2019 base year. As we scale to serve more patients globally, our emissions have grown, however key initiatives such as next-generation propellant (NGP) transition are on track.	Lagging
Reduce absolute Scope 3 GHG emissions by 90% from 2019 base year.	2045	We are aiming to deliver the scale of emissions reduction required through a phased approach over the long term.	
Increase the share of primary activity data in Scope 3 reporting.	2025	69% of Scope 3 data came from primary sources.	Target met
95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have science-based targets (SBTs).	2025	Although the target was not met, over 80% of eligible spend comes from suppliers committed to SBTs. Specifically, 68% of our spend on purchased goods and services and capital goods, 65% on upstream transportation and distribution, and 42% on business travel are with suppliers who have verified SBTs. This demonstrates our ongoing engagement with suppliers to support decarbonisation and lays a solid foundation for progress beyond 2025.	Target not met
Launch a next-generation propellant (NGP) inhaler to treat asthma and Chronic Obstructive Pulmonary Disease (COPD) containing a near-zero Global Warming Potential (GWP) propellant.	2025	In 2025, we announced the world-first approval by the UK Medicines and Healthcare products Regulatory Agency and a Committee for Medicinal Products for Human Use positive opinion for Trixeo Aerosphere to be used with the NGP, endorsing it for use in the EU and marking the initiation of the transition of our full portfolio to the NGP, with submissions for transitioning Breztri/Trixeo in other territories underway.	Target met
Ensure 90% of total syntheses meet resource efficiency targets at launch.	2025	67% of total syntheses met resource efficiency targets at launch (out of 12 total syntheses since 2015). Continuous improvement work is ongoing in process development functions to maximise resource efficiency. We are continuously balancing the provision of medicines to patients at the earliest opportunity whilst minimising their environmental impact.	Target not met
Ensure 95% of paper-based product packaging materials used are supplied from sustainable sources.	2025	97% of paper-based product packaging materials used are supplied from sustainable sources.	Target met
Ensure 100% of AstraZeneca site discharges and ≥90% of supplier site discharges are in compliance with safe API discharge concentrations.	2025	100% of API discharges from AstraZeneca sites and 95% of discharges from direct suppliers were in compliance. Supplier non-compliance reflects suppliers who exceeded safe discharge levels. AstraZeneca continually collaborates with suppliers to improve their API discharge.	Target met
Reduce water withdrawal by 20% below the 2015 baseline.	2025	Water withdrawal was 3.44 million m ³ , a 23% reduction from 2015.	Target met
Reduce waste by 10% below the 2015 baseline.	2025	Total waste was 23,409 tonnes, a 23% reduction from 2015.	Target met
Plant and maintain 200 million trees.	2030	Over 66 million trees were planted through AZ Forest since 2020.	Lagging
All 12 key materials within our Raw Materials Sustainable Sourcing Framework have sustainability action plans in place.	2025	Sustainable Sourcing Frameworks developed for 12 key raw materials by December 2025.	Target met
All of our sites with labs operate My Green Labs.	2025	104 labs are My Green Lab certified; 97 at Green level.	Target met

Scope 1, 2 and other GHG emissions (tonnes CO₂e)		2015	2023	2024	2025
Scope 1 – Road fleet		92,539	47,758	31,337	15,935
Scope 1 – Site energy		167,441	92,569	73,167	36,368
Scope 1 – Site non-energy		38,519	40,571	20,880	10,284
Scope 1 – Total		298,498	180,898	125,386	62,587
Scope 2 – Market based		322,319	19,940	14,210	11,316
Gross Scope 1 and 2 GHG emissions (Market-based)	SDG 13.2	620,818	200,838	139,594	73,903 Δ
Scope 1 and 2 GHG emissions intensity (tonnes CO ₂ e per million of Total Revenue) ¹	SDG 13.2	22.73	4.38	2.58	1.26
Scope 2 – Location based		266,372	183,332	217,026	241,023
Biogenic emissions (Outside of scopes emissions)		2,822	29,201	75,978	105,850
Road fleet		2015	2023	2024	2025
EV100: Battery electric vehicles (BEVs)		0%	35%	63%	81.5%
Energy consumption (MWh)		2015	2023	2024	2025
Total energy consumption from fleet		—	219,987	209,390	141,955
Total energy consumption from sites		1,832,611	1,513,338	1,466,686	1,470,181
Total energy consumption		—	1,733,325	1,676,076	1,612,136
Site energy management		2015	2023	2024	2025
EP100: Energy productivity (million of Total Revenue per GWh energy consumption)	SDG 7.3	14.90	30.27	36.87	39.95
Renewable energy consumption – electricity and heat (MWh)		130,301	802,658	1,024,432	1,216,901
Imported electricity – renewable		16%	99%	99%	99%
RE100: Renewable electricity consumption ²	SDG 7.2	15%	95%	94%	94%
Onsite self-generated electricity from non-renewable sources (MWh)		68,445	34,869	14,618	14,010
Scope 3 GHG emissions (tonnes CO₂e)³		2019	2023	2024	2025
Category 1 – Purchased goods and services		2,772,522	3,302,771	3,313,099	3,394,405
Category 2 – Capital goods		217,787	221,017	327,689	480,217
Category 3 – Fuel and energy related (not Scope 1 or 2)		80,556	52,635	47,992	48,797
Category 4 – Upstream transportation and distribution		256,377	207,221	228,219	210,873
Category 5 – Waste generated in operations		19,661	19,043	24,487	23,417
Category 6 – Business travel		401,730	181,583	199,248	207,819
Category 7 – Employee commuting		46,461	50,827	51,387	51,510
Category 8 – Upstream leased assets		17,753	8,382	8,490	10,381
Category 9 – Downstream transportation and distribution ⁴		133,627	135,689	120,730	127,432
Category 10 – Processing of sold products			Assessed: Not relevant		
Category 11 – Use of sold products		1,037,501	1,395,261	1,377,449	1,621,632
Category 12 – End-of-life treatment of sold products		16,122	14,579	15,713	19,531
Category 13 – Downstream leased assets		25,072	2,063	1,708	1,676
Category 14 – Franchises			Assessed: Not relevant		
Category 15 – Investments			Assessed: Not material		
Gross Scope 3 GHG emissions⁵	SDG 13.2	5,025,169	5,591,071	5,716,211	6,197,690 Δ
Scope 3 GHG emissions intensity (tonnes CO ₂ e per million of Total Revenue) ¹		171.1	122.0	105.7	105.5
Share of primary activity data in Scope 3 reporting		51%	62%	64%	69% Δ

¹ Following the rebaselining of emissions to include the Alexion acquisition, the intensity metric incorporates Alexion's Revenue from the baseline year.

² 2024 data has been revised, for further details please refer to the data and methodology adjustments section of the Sustainability Data Reporting Criteria 2025.

³ Data has been revised due to improvements in methodology to enhance data quality. For more information, please refer to the Sustainability Data Reporting Criteria 2025.

⁴ Category 9 is excluded from the 2030 and 2045 target boundary.

⁵ Scope 3 GHG emissions (excluding Category 9) was 6,070,258 tCO₂e.

Supply chain engagement (% spend with verified SBTs)		2023	2024	2025	
Category 1 – Purchased goods and services		29%	46%	68%	
Category 2 – Capital goods					
Category 4 – Upstream transportation and distribution		27%	30%	65%	
Category 6 – Business travel ⁶		32%	40%	42%	
Safe active pharmaceutical ingredients (API) discharges		2023	2024	2025	
Safe API discharges for AstraZeneca sites	SDG 6.3	99%	100%	100%	
Safe API discharges from suppliers	SDG 6.3	94%	91%	95%	
Number of safe API discharge supplier assessments completed		70	65	60	
Resource efficiency		2023	2024	2025	
Total syntheses that meet resource efficiency target at launch	SDG 12.2	64%	64%	67%	
Product value chain environmental impact		2023	2024	2025	
Percentage of product sales revenue for brands scored against Product Sustainability Index ⁷			71%	79%	
Percentage of product sales revenue for brands with lifecycle assessment completed ⁷			87%	91%	
Paper-based product packaging materials supplied from sustainable sources	SDG 15.2	98%	96%	97%	
Water withdrawal within site water footprint, excluding non-contact cooling water		2015	2023	2024	2025
Municipal (million m ³)		3.66	3.12	2.95	3.03
Groundwater (million m ³)		0.77	0.44	0.43	0.38
Rainwater (million m ³)		0.03	0.04	0.05	0.03
Total (million m³)⁸	SDG 6.4	4.46	3.59	3.43	3.44 •
Chemical oxygen demand – effluent leaving our sites (tonnes)		196	556	614	1,244
Non-contact cooling water (million m³)		2015	2023	2024	2025
Direct from fresh surface water – volume fully returned after use		9.48	9.19	8.00	8.85
Water withdrawal by water scarcity rating for sites with over 10,000 m³ water per year (including non-contact cooling water)		2023	2024	2025	
High scarcity rating (m ³)	SDG 6.4	57,191	54,408	52,413	
Medium scarcity rating (m ³)	SDG 6.4	81,762	91,821	80,751	
Percentage of water withdrawal by AstraZeneca in medium and high scarcity rating areas	SDG 6.4	1.1%	1.3%	1.1%	
Waste management		2015	2023	2024	2025
Total waste (tonnes)⁸		30,217	26,213	26,285	23,409
Total recycling (tonnes)	SDG 12.5	13,537	10,941	10,659	9,587
Total recycling as a percentage of total waste	SDG 12.5	45%	42%	41%	41%
Total waste to landfill (tonnes)		2,153	1,136	1,339	688
External waste avoided – reuse and by-product (tonnes) ⁷	SDG 12.5			6,029	6,103

⁶ 2024 data has been revised, for further details please refer to the data and methodology adjustments section of the Sustainability Data Reporting Criteria 2025.

⁷ Metric first disclosed from 2024.

⁸ Total waste consists of the total amount of waste recycled, sent to landfill, and incinerated with or without energy recovery, as well as waste categorised as other treatment.

Non-hazardous waste (tonnes)		2015	2023	2024	2025
Total non-hazardous waste⁹		22,148	16,552	16,557	15,022 •
Non-hazardous waste recycled		13,242	10,009	9,617	8,546
Non-hazardous waste to landfill		2,126	1,121	1,286	556
Hazardous waste (tonnes)		2015	2023	2024	2025
Total hazardous waste⁹		8,069	9,661	9,728	8,388 •
Hazardous waste recycled		295	932	1,042	1,041
Hazardous waste to landfill		27	15	53	132
Green Labs Programme			2023	2024	2025
Number of My Green Lab certifications			108	129	104
AZ Forest (cumulative, million)			2023	2024	2025
Number of trees planted	SDG 15.2		20	40	66
Compliance Summary			2023	2024	2025
Prosecution			0	0	0
Enforcement action			0	0	0
Regulatory warning or alert			4	1	0
Major external Safety, Health and Environmental compliance violation			1	1	0
Awaiting regulatory outcome			0	2	0
Environmental violations			0	0	0
Financial penalties relating to above (USD)			0	0	0

⁹ Total hazardous and total non-hazardous waste each consists of waste recycled, sent to landfill, and incinerated with or without energy recovery, as well as waste categorised as other treatment.

Health equity and Health systems resilience

Target	Year	Progress	Status
Positively impact 1 billion people, including 400 million people from underserved groups.	2030	We've positively impacted over 320 million people cumulatively since 2024, of which 156 million people were from underserved groups.	On plan
Strengthen health systems in 45 countries through partnerships with governments and evidence-based advocacy.	2030	As of 2025, 36 countries have active Partnership for Health System Sustainability and Resilience (PHSSR) programmes, including health system assessments and policy reports on the roadmap to acting early on non-communicable diseases (NCDs).	On plan
Reach 50 million people (cumulative) through Healthy Heart Africa, Young Health Programme (YHP), Healthy Lung and Phakamisa.	2025	Target was met in 2023, two years ahead of schedule.	Target met
Train 170,000 healthcare workers (cumulative) to strengthen health systems throughout the world.	2025	Target met in 2025, we have trained over 180,000 healthcare workers.	Target met

Accessible and affordable healthcare (cumulative, million)¹⁰	2025
Number of people positively impacted	320 Δ
Number of people positively impacted from underserved groups	156 Δ

People reached by access to healthcare programmes (cumulative, million)	2023	2024	2025	
Healthy Heart Africa	48	67	81	
Young Health Programme	15	20	24	
Total people reached (all current and historic programmes)	SDG 3.8	66	90	108

Healthcare workers trained (cumulative, thousand)	2023	2024	2025	
Total healthcare workers trained (all current and historic programmes)	SDG 3.c	127	157	180

Affordability (cumulative, million)	2023	2024	2025	
People reached by patient access programmes	SDG 3.8	13.7	14.2	14.7

Philanthropy	2023	2024	2025
Total community investment (USD, million)	115	127	90
Non-profit organisations funded by AstraZeneca	811	928	882

¹⁰ Metric first disclosed from 2025, figures are cumulative with 2024 as the baseline year, and encompass all historical data since then.

How we do business

Target	Year	Progress Update	Status
Maintain 100% of active employees trained on the Code of Ethics.	2025	100% of active employees trained on the Code of Ethics in 2025.	Target met
Ensure AstraZeneca has a 'speak up' culture.	2025	83% of employee survey respondents feel we have a 'speak up' culture.	Target met
Improve the AstraZeneca global biennial human rights survey results and use Fair Wage Network data to more robustly assess our performance against local living wage data.	2025	The Human Rights Survey has enabled us to validate our position regarding compliance with standards established by the International Labour Organization (ILO). Over the years since we started the survey, we have observed improvements in certain themes, including countries introducing mental health support programmes, and the provisions for paid family leave for the secondary parent.	Target met
Our Sustainable Procurement programme aims for 100% ethical spend by embedding sustainability into end-to-end processes.	2025	Though we were not able to achieve our ambitious target, we made substantial progress against our Sustainable Procurement ambition of working with companies who demonstrate ethical business management. 78% of supplier spend is now with companies assessed by EcoVadis as having an acceptable ESG rating, supporting continued integration of sustainability into procurement practices.	Target not met
Reach gender equality in management positions.	2025	52% of senior middle management roles and above are filled by women. Target was met two years ahead of schedule.	Target met
Launch supplier diversity programmes in 10 new countries (outside of the US).	2025	Target was met in 2023, two years ahead of schedule.	Target met
75% reduction in total injury rate from 2015 baseline.	2025	Over the past decade, we strengthened safety performance, reducing our total incident rate by 59%, with no fatal or serious (life-changing) injuries reported in 2025. While long-term (10 year) reduction targets were not fully met, we remain committed to a safe workplace where risk management is embedded to drive continuous improvement.	Target not met
55% reduction in collisions per million kilometres from 2015 baseline.	2025	We have seen a 50% reduction in our collision rate over the last decade and no fatal or serious (life changing) injuries reported in 2025. While the long term (10 year) reduction target was not fully met, we continue to invest in technology, training and monitoring to keep our drivers and the community safe.	Target not met

Sustainable innovation	2024	2025	
Number of new molecular entities (NMEs) approvals (cumulative)	8	9 Δ	
Number of pipeline progression events	24	38 Δ	
Number of regulatory events	74	97 Δ	
Patient safety and product quality	2024	2025	
Number of inspections from health authorities relating to Good Manufacturing Practice and Good Distribution Practice ¹¹	49	63 Δ	
Number of critical findings from health authorities relating to Good Manufacturing Practice and Good Distribution Practice ¹¹	0	0 Δ	
Number of product recalls	7	10 Δ	
Cybersecurity and data privacy	2024	2025	
Number of material cybersecurity incidents	0	0 Δ	
Number of material security breaches involving personal data	0	0 Δ	
People	2023	2024	2025
Employee belief that in the last 12 months, I have improved my existing skills, or learned new skills, or had a development opportunity	88%	88%	89% Δ
Employee belief that AstraZeneca is a great place to work	86%	84%	86% Δ

¹¹ The metric name and boundary was updated following the integration of the inspections on marketing company into the population of the data set.

Business conduct		2023	2024	2025
Active employees trained on Code of Ethics		100%	100%	100%
Instances of non-compliance with the Code of Ethics		3,756	3,853	4,441
Concerns reported through the company helpline ¹²		473	862	1,264
Percentage of employees who feel we have a 'speak up' culture		83%	82%	83%
Clinical trial transparency (cumulative)				
		2023	2024	2025
Studies shared with external research teams		270	296	312
Publicly available trial summaries		401	506	582
Human rights				
		2023	2024	2025
Countries that completed the human rights survey	SDG 8.8	—	72	—
Countries that have a relationship with trade unions	SDG 8.8	—	29%	—
Responsible supply chain				
		2023	2024	2025
High-risk supplier audits		47	59	52
Percentage suppliers by spend assessed by EcoVadis		70%	77%	80%
Percentage suppliers by spend assessed by EcoVadis that achieve >45		66%	73%	78%
Animal use standards				
		2023	2024	2025
In-house research (number of animals)		122,768	141,947	138,356
External contract research (number of animals)		59,690	63,810	63,869
Total number of animals		182,458	205,757	202,225
Human biological samples				
		2023	2024	2025
Active projects using human foetal tissue (hFT)		3	3	2
Active projects using human embryonic stem cells (hESC)		13	5	3
Inclusion and diversity				
		2023	2024	2025
Women representation of AstraZeneca employees		54%	54%	54%
Women in management – All management levels	SDG 5.5	47%	47%	48%
Women in management – Senior middle management	SDG 5.5	50%	51%	52%
Women in management – Executive management	SDG 5.5	42%	42%	43%
Women representation on Senior Executive Team (SET)	SDG 5.5	42%	50%	50%
Women representation on Board of Directors	SDG 5.5	46%	46%	50%
Share of women in STEM-related positions	SDG 5.5	41%	40%	40%
Share of women in management positions in revenue-generating functions	SDG 5.5	48%	49%	49%
Share of women in junior management positions, i.e. first level of management	SDG 5.5	45%	46%	46%
Ethnic minority representation for US employees		37%	38%	39%
Percentage of employees age <30		17%	16%	14%
Percentage of employees age 30-49		62%	63%	65%
Percentage of employees age ≥50		21%	21%	21%
Countries with supplier diversity programmes		11	21	21

¹² 2024 data has been revised, for further details please refer to the data and methodology adjustments section of the Sustainability Data Reporting Criteria 2025.

Workforce safety and health		2023	2024	2025
Total reportable injury rate (per million hours worked) (employees) ¹³	SDG 8.8	0.80	0.82	0.73
Collisions (per million kilometres driven) ¹³	SDG 3.6	2.15	1.99	2.06
Occupational illness rate (per million hours worked) (employees) ¹³		0.18	0.13	0.03
Lost time injury rate (per million hours worked) (employees) ¹³		0.42	0.36	0.32 •
Lost time injury rate (per million hours worked) (construction contractors)		3.41	1.42	0.98
Fatalities (employees)	SDG 8.8	0	0	0 •
Fatalities (construction contractors)	SDG 8.8	0	0	0 •
Employee satisfaction				
		2023	2024	2025
Employees that have at least one quality development discussion with their line manager		89%	88%	88%
Employee belief in our strategy		89%	87%	89%
Sustainability engagement survey score		87%	87%	89%
Talent attraction and retention				
		2023	2024	2025
Total amount spent on upskilling employees (USD, million) ¹⁴			108	111
Total learning hours		2,040,956	4,391,124	3,851,089
Average learning hours		18	34	29
Employee overall promotion rate		7.7%	6.5%	5.5%
Employee turnover		12.6%	10.9%	11.0%
Voluntary employee turnover – recent hires		9.8%	8.2%	7.5%
Voluntary employee turnover – total		7.5%	6.1%	5.8%
US Food and Drug Administration (FDA) Statistics				
		2023	2024	2025
FDA Class I Recall		0	0	0
FDA Class II Recall		0	0	2
FDA Class III Recall		0	0	0
Total FDA recalls		0	0	2
Total FDA observations		8	12	0
Total FDA inspections		7	4	3
Quality manufacturing				
		2023	2024	2025
Internal quality audits of AstraZeneca suppliers		561	449	520
Internal quality audits of AstraZeneca sites		76	53	76

¹³ Prior year's data has been revised, for further details please refer to the data and methodology adjustments section of the Sustainability Data Reporting Criteria 2025.

¹⁴ New methodology from 2024.